Skip to main navigation
Skip to search
Skip to main content
Sort by
Medicine and Dentistry
Biological Marker
100%
Hepatocellular Carcinoma
100%
Combination Therapy
100%
Immunocompetent Cell
100%
Nivolumab
100%
Diseases
100%
Programmed Death 1 Ligand 1
80%
Disease Exacerbation
60%
B Cell
40%
Flow Cytometry
20%
Immunotherapy
20%
Clinical Trial
20%
Cytotoxic T-Cell
20%
T Cell
20%
T-Helper Cell
20%
Advanced Cancer
20%
Lymphocyte
20%
Keyphrases
Treatment Efficacy
100%
Programmed Death-ligand 1 (PD-L1)
100%
Advanced Hepatocellular Carcinoma
100%
Circulating Immune Cells
100%
Nivolumab
100%
Disease Progression
37%
Disease Control
37%
Monocytes
25%
Non-associated
25%
Peripheral B Cells
25%
Treatment Outcome
25%
Flow Cytometry
12%
Clinical Trials
12%
T Cells
12%
CD8+ T Cells
12%
Lymphocytes
12%
Partial Response
12%
Peripheral Blood
12%
Immune Cells
12%
Complete Response
12%
Stable Disease
12%
Advanced Cancer
12%
Objective Response Rate
12%
Disease Control Rate
12%
Days of Treatment
12%
Hemogram
12%
CD4 T Cells
12%
Anti-programmed death-1 Monoclonal Antibody
12%
Pharmacology, Toxicology and Pharmaceutical Science
Liver Cell Carcinoma
100%
Combination Therapy
100%
Biological Marker
100%
Nivolumab
100%
Diseases
100%
Programmed Death 1 Ligand 1
80%
Disease Exacerbation
60%
Immunotherapy
20%
Clinical Trial
20%
CD8 Antigen
20%
Flow Cytometry
20%
Advanced Cancer
20%
Immunology and Microbiology
Immunocompetent Cell
100%
Programmed Death 1 Ligand 1
100%
Nivolumab
100%
B Cell
50%
Immunotherapy
25%
Cytotoxic T-Cell
25%
T Cell
25%
T-Helper Cell
25%
Lymphocyte
25%